CHNA China Biopharma ETF

Seeks to track, before fees and expenses, the Loncar China BioPharma Index, an index of 28 securities that have a strategic focus on advancing China’s biopharma industry. With a focus on innovators, the index contains globally listed pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers, distributors and service providers that have a strategic role in growing China’s drug industry. The Index includes stocks traded in the U.S. and Hong Kong but not in China. Stocks must have a minimum market cap of $200 million. All companies are initially given equal weight and then weighting factors are applied based on market capitalization categories. Companies with a market capitalization greater than $10 billion are given a weighting factor of 1.4, companies with a market capitalization between $1 billion and $10 billion are given a weighting factor of 1.0, and companies with a market capitalization between $200 million and $1 billion are given a weighting factor of 0.7.

$17.71
As of 05/20/2022     IEX book   CBOE book

---

ETF Information

---

Sponsor:     Loncar Funds
Category1:  Global Equity
Category2:  Single country
Category3:  Health care
Morningstar category:  China Region
Country:      China
Leverage factor:  1.00
Inception date:  08/14/2018
Index tracking method: Passive replication
Current yield:  17.12%
Historical average yield:  3.05%
Market cap:  $5,391,000
Average volume:  5,431
Fees:     0.7900%

---

Index Information

---

Loncar China BioPharma Index
Index symbol:  LCHINA
Provider:   Loncar Investments
Index weighting:   Other
Index inception date:  02/13/2018
Backtesting data exists:   No
Number of holdings:  29  (as of 11/20/2018)
Rebalanced:  Semi-annually
Reconstituted:  Semi-annually